Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | F11 | P03951 | 3/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29672463 | 1.00 | F2 (0.42) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL457989 | 0.85 | P2RX7 (0.55) | P2RX7MAPK1TSHRGABRR1GABRP | |
| Hydrochloric Acid SCHEMBL2631288 | 0.84 | P2RX7 (0.53) | P2RX7MAPK1TSHRGABRR1GABRP | |
| Trifluoroacetic Acid SCHEMBL17243108 | 0.78 | F2 (0.42) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL25166342 | 0.76 | P2RX7 (0.61) | P2RX7MAPK1 | |
| Hydrochloric Acid SCHEMBL31645848 | 0.75 | P2RX7 (0.59) | P2RX7MAPK1 | |
| SCHEMBL2029150 | 0.74 | USP30 (0.37) | P2RX7MAPK1 | |
| SCHEMBL12791545 | 0.69 | P2RX7 (0.48) | P2RX7MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6215734 | 0.69 | TSHR (0.58) | MAPK1TSHRGABRR1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL29043350 | 0.68 | P2RX7 (0.47) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2024-01-23 | — | — | US | disclosed |
| CN-116437918-A | Pyrazolopyridine compounds as TAM inhibitors | 上海德琪医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023051464-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2023-04-06 | — | — | WO | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2022-11-15 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| EP-2785715-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080222-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-06-06 | — | — | WO | disclosed |
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2064203-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032091-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | F12, FAR1, NQO2 | F2 396/4885F11 78/4885PRSS1 522/4885 |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | F2 2722/4885F11 667/4885PRSS1 1101/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | F2 4658/4885F11 2696/4885PRSS1 2534/4885 |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | F2 4658/4885F11 2696/4885PRSS1 2534/4885 |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | F2 4641/4885F11 2607/4885PRSS1 2295/4885 |
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | F2 1944/4885F11 2632/4885PRSS1 3214/4885 |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | F2 4658/4885F11 2696/4885PRSS1 2534/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | F2 4658/4885F11 2696/4885PRSS1 2534/4885 |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | F2 2743/4885F11 2493/4885PRSS1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.